Recent advances in immunotherapy and combination therapies are revolutionizing the treatment landscape for both metastatic ...

Distant metastasis-free survival ... support for adjuvant [Opdivo] as a standard of care for patients with high-risk ...

In a phase 3 trial, more deaths due to adverse events were reported in the Trodelvy arm compared with the chemotherapy arm. Gilead has made the decision to withdraw the accelerated approval of ...

Gilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer. Trodelvy (sacituzumab govitecan) has been approved for locally ...

The issue to discuss here is if the metastasis should have been resected ... However, over 50% of patients with urothelial cancer are 'unfit' (a GFR less than 60 mL/min and/or a performance ...

Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer. October 28th 2022EP. 2: Unmet Needs of Patients with Locally ...

Last month, manufacturer Gilead Sciences announced the voluntary withdrawal of the FDA’s accelerated approval of Trodelvy for the treatment of locally advanced or metastatic urothelial cancer, a type ...

Therefore future research should also try to assess whether class I HDACs have a prognostic value in locally advanced invasive or metastatic urothelial cancer.